Targeting p160 SRCs in prostate cancer with bufalin (2)
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147213
下载链接
链接失效反馈官方服务：
资源简介：
The p160 Steroid Receptor Coactivators SRC-1, SRC-2, and SRC-3 are critical components of the AR transcriptional complex and are frequently upregulated in prostate cancer (PC). We showed that inhibition of the SRCs via a small molecule inhibitor significantly diminishes AR signaling output, expression of CRPC-associated transcripts and proliferation of CRPC cells both in vitro and in vivo. LNCaP MDV-3100/enzalutamide-resistant (MDV-R) cells were treated with 10 nM bufalin or control for 48h.
创建时间：
2025-03-15
